Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study

Bibliographic Details
Main Author:	Małgorzata Wisłowska
Format:	Article
Language:	English
Published:	Termedia Publishing House 2022-05-01
Series:	Rheumatology
Subjects:	severe rheumatoid arthritis biological agents jak-stat inhibitors diseasemodifying antirheumatic drugs.
Online Access:	https://www.termedia.pl/Comparison-of-treatment-of-severe-rheumatoid-arthritis-patients-with-biological-agents-and-JAK-STAT-inhibitors-An-observational-study,18,46973,1,1.html

Similar Items

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
by: Małgorzata Wisłowska
Published: (2024-11-01)

Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study
by: Wen Qi, et al.
Published: (2024-08-01)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
by: Rita A. Moura, et al.
Published: (2021-02-01)

Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study
by: Boulos Haraoui, et al.
Published: (2024-11-01)

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
by: Bong-Woo Lee, et al.
Published: (2024-09-01)

Editor’s Pick: JAK Inhibitors in the Treatment Algorithm of Rheumatoid Arthritis: A Review
by: Salvatore Bellinvia, et al.
Published: (2018-07-01)

JAK inhibitors for the treatment of rheumatoid arthritis
by: Akio Morinobu
Published: (2020-10-01)

JAK ACADEMY in Rheumatoid Arthritis (RA)
by: Roberto Caporali, et al.
Published: (2018-09-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2023-07-01)

Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors
by: Blaž Burja, et al.
Published: (2020-05-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

New bitongling (NBTL) ameliorates rheumatoid arthritis in rats through inhibiting JAK2/STAT3 signaling pathway
by: Xiang Li, et al.
Published: (2021-02-01)

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients
by: María Ángeles González-Fernández, et al.
Published: (2019-01-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis
by: Maurizio Benucci, et al.
Published: (2023-08-01)

Suberosin attenuates rheumatoid arthritis by repolarizing macrophages and inhibiting synovitis via the JAK/STAT signaling pathway
by: Huan Liu, et al.
Published: (2025-01-01)

A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs
by: Louis Bessette, et al.
Published: (2024-07-01)

New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors
by: Masaru Kato
Published: (2020-04-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2/Stat3 signaling pathway
by: Hongli Liu, et al.
Published: (2023-08-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study
by: Yusuke Kashiwado, et al.
Published: (2022-06-01)

JAK/STAT in leukemia: a clinical update
by: Dong Liang, et al.
Published: (2024-01-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
by: Shuhei Yoshida, et al.
Published: (2023-10-01)

Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
by: Kichul Shin, et al.
Published: (2020-01-01)

Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
by: Richard Conway, et al.
Published: (2021-01-01)

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
by: Maaria Palmroth, et al.
Published: (2021-09-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Vascular synovial phenotype indicates poor response to JAK inhibitors in rheumatoid arthritis patients: a pilot study
by: Mengxia Liu, et al.
Published: (2024-11-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Chrysoeriol suppresses hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes and inhibits JAK2/STAT3 signaling
by: Jia-Ying Wu, et al.
Published: (2022-03-01)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
by: Harrington R, et al.
Published: (2020-09-01)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
by: Irma Convertino, et al.
Published: (2023-03-01)

LncRNA ZNF667-AS1 alleviates rheumatoid arthritis by sponging miR-523-3p and inactivating the JAK/STAT signalling pathway
by: Qin Zhuo, et al.
Published: (2021-10-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Periodontal Indices in Patients with Rheumatoid Arthritis Undergoing Immunosuppressive Therapy
by: Ilnaz Frahoudi, et al.
Published: (2024-06-01)

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
by: Kichul Shin, et al.
Published: (2022-09-01)

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
by: Martin E. Dowty, et al.
Published: (2019-12-01)